Full Press Release Details
Alpha Tau Reports New Positive Results in Two
Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer
- Final results from first pancreatic cancer
study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients -
- Immune markers demonstrate immune system preservation
not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect -
- Alpha DaRT currently being studied together
with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer -
Jerusalem, January 6, 2026 - Alpha
Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha
DaRT today announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada
exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC). The results have been published as two abstracts
and will be presented at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8 - 10, 2026.
Study Principal Investigator Corey Miller, MD, MSc, Director of Therapeutic
Endoscopy of the Division of Gastroenterology of the JGH, Assistant Professor of Medicine at McGill University, Associate Researcher at
the Lady Davis Institute, will lead a presentation entitled "Feasibility, Safety and Efficacy of Endoscopic Ultrasound-Guided
Alpha Radiotherapy for Advanced Pancreatic Cancer: A Pilot Study" with final clinical results of the Company's trial.
In the trial, 32 patients with Stage II, III or IV PDAC were treated, many of whom had one or more prior rounds of chemotherapy. The results
demonstrate a 22% objective response rate (ORR) and an 81% disease control rate (DCR) across all 32 patients treated in the study, or
23% ORR and 87% DCR when excluding the first two patients, who were deliberately given low dosages in order to examine feasibility and
The Company is further exploring the use of Alpha DaRT in treating
PDAC in its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating
the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally
advanced or metastatic pancreatic adenocarcinoma, as well as in other clinical studies in Europe. Additional information about the IMPACT
trial can be found at https://clinicaltrials.gov/study/NCT06698458.
"We are very excited about the results of the study, in which
we were the first clinicians to deliver Alpha DaRT via endoscopic ultrasound into the pancreas," added Dr. Miller. "The results
indicate that Alpha DaRT is a technically feasible treatment of pancreatic cancer, with a strong safety profile and encouraging local
disease control. We look forward to further exploration of the use of Alpha DaRT for PDAC patients in the IMPACT trial as well as future
trials, with the potential to generate a meaningful data set focused on a specific patient population with newly diagnosed disease."
In addition, in a presentation entitled "Inflammatory and
Immune Marker Dynamics following Intratumoral Alpha DaRT for Pancreatic Cancer", Kim Anh Ma, MD, Assistant Professor of Oncology
at Jewish General Hospital in Montreal, will present results showing the immune-preserving profile of Alpha DaRT in PDAC, based on immune
markers as well as inflammatory indices known to be negative prognostic indicators, and which typically worsen after other forms of radiation
therapy. In a study of 23 PDAC patients treated with Alpha DaRT who had complete laboratory data, one month following Alpha DaRT treatment,
investigators observed no significant change in Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, CD4/CD8 T-cell ratio, or
C-Reactive Protein levels, demonstrating immune system preservation not typical of conventional radiation therapy treatments. Moreover,
low post-treatment levels of some of these indices were associated with favorable disease control. Furthermore, a dramatic drop in levels
of IL-6 cytokine (p<0.000001), a key mediator of inflammation, suggested a potential reduced inflammatory effect.
Dr. Ma noted, "It is quite unique to find a radiation therapy
with reduced inflammatory profile and no observed increase in negative prognostic factors, typically linked to radiation-induced lymphopenia.
This may enable, or even support, other systemic therapies, such as immunotherapy, and may also help explain anecdotes where systemic
response to chemotherapy appeared to improve after insertion of Alpha DaRT into the primary tumor in the pancreas."
Uzi Sofer, CEO of Alpha Tau, stated, "Exploring the treatment
of pancreatic cancer remains a cornerstone of our strategy for Alpha DaRT, with multiple clinical trials being pursued in parallel, led
by our flagship IMPACT trial, which continues to see an excellent pace of recruitment. We look forward to generating further data in this
indication in 2026 and forging ahead toward a potential future approval in this key indication."
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company
that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology
was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed
to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When
the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with
the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor,
and to spare the healthy tissue around it.
Forward-Looking Statements
This press release includes "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate,"
"will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer to the Alpha DaRT treatment in pancreatic patients, including the potential
benefits and associated risks, future applications and uses, the IMPACT study and potential indication approvals , are forward-looking.
All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there
is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations,
and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking
statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory
approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history;
(iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise
capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence
on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical
studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future
clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha
Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement
lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's
listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important
factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March
12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important
factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.
Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect
to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so,
even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha
Tau's views as of any date subsequent to the date of this press release.
Investor Relations Contact: